Advanced Biomed Inc. (NASDAQ:ADVB) Stock Short Interest Report for October

Advanced Biomed Inc. (NASDAQ:ADVB) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 9,747 shares, a drop of 48.4% from the September 30th total of 18,897 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 16,412 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ADVB shares. Weiss Ratings cut shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. Wall Street Zen cut Advanced Biomed from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.

Advanced Biomed Price Performance

Shares of Advanced Biomed stock traded down $0.11 during trading hours on Monday, hitting $2.19. The company’s stock had a trading volume of 3,535 shares, compared to its average volume of 713,774. Advanced Biomed has a 12 month low of $2.25 and a 12 month high of $24.23. The stock has a 50 day moving average of $6.52 and a 200 day moving average of $5.91. The company has a market capitalization of $3.61 million, a PE ratio of 0.45 and a beta of 0.70.

Advanced Biomed (NASDAQ:ADVB) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $0.44 earnings per share (EPS) for the quarter.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.